NAV

Brolucizumab

Targets (1)

Identification

Name
Brolucizumab
Accession Number
DB14864
Description

Brolucizumab, also known as RTH258 or ESBA1008,4 is a monoclonal antibody indicated to treat neovascular age related macular degeneration.6

Brolucizumab was granted FDA approval in October 2019.6

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
26000.0 Da (approximate)
Sequences
Not Available
Synonyms
  • Brolucizumab
  • brolucizumab-dbll
External IDs
  • ESBA-1008
  • ESBA1008
  • RTH-258
  • RTH258

Pharmacology

Indication

Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration.3,6

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which reduces proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.6 It has a long duration of action as it is given monthly.6 Patients should be counselled regarding the risk of endophthalmitis, retinal detachment, and arterial thromboembolic events following administration of this medication.6

Mechanism of action

Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165.1,3,6 Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.6

TargetActionsOrganism
AVascular endothelial growth factor A
inhibitor
Humans
Absorption

A 3mg dose of brolucizumab reaches a Cmax of 20.7ng/mL with a Tmax of 20.3h and an AUC of 2480ng*h/mL.7 A 6mg dose of brolucizumab reaches a Cmax of 77.6ng/mL with a Tmax of 17.4h and an AUC of 9169ng*h/mL.7

Volume of distribution

Data regarding the volume of distribution is not readily available.6

Protein binding

Monoclonal antibodies are generally not protein bound in serum.2

Metabolism

Monoclonal antibodies are expected to undergo proteolysis to smaller peptides and amino acids.2

Route of elimination

Data regarding the route of elimination is not readily available.6 Monoclonal antibodies are generally not eliminated in the urine, and only a small amount is excreted in bile.5

Half-life

The systemic half life of bolucizumab is 4.4±2.0 days.6 The elimination half life is 108h for a 3mg dose and 103h for a 6mg dose.7

Clearance

Data regarding the clearance of brolucizumab is not readily available.6

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Data regarding the toxicity of brolucizumab is not readily available.6

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Unlock Additional Data
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Brolucizumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Brolucizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brolucizumab.
Alendronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Alendronic acid.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Brolucizumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Brolucizumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Brolucizumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Brolucizumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brolucizumab.
Asfotase alfaThe risk or severity of adverse effects can be increased when Asfotase alfa is combined with Brolucizumab.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Unlock Additional Data
BeovuSolution6 mgIntravitrealNovartisNot applicableNot applicableCanada flag
BeovuInjection, solutionIntravitrealNovartis Europharm Limited2020-02-13Not applicableEU flag
BeovuSolution6 mgIntravitrealNovartis2020-05-15Not applicableCanada flag
BeovuInjection, solution6 mg/0.05mLIntravitrealNovartis Pharmaceuticals Corporation2019-10-07Not applicableUS flag
BeovuInjection, solutionIntravitrealNovartis Europharm Limited2020-02-13Not applicableEU flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
S01LA06 — Brolucizumab
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
XSZ53G39H5
CAS number
1531589-13-5

References

General References
  1. Perrot-Applanat M: VEGF isoforms. Cell Adh Migr. 2012 Nov-Dec;6(6):526-7. doi: 10.4161/cam.23256. Epub 2012 Nov 1. [PubMed:23257829]
  2. Tabrizi MA, Tseng CM, Roskos LK: Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006 Jan;11(1-2):81-8. doi: 10.1016/S1359-6446(05)03638-X. [PubMed:16478695]
  3. Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, Singerman L: Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology. 2017 Sep;124(9):1296-1304. doi: 10.1016/j.ophtha.2017.03.057. Epub 2017 May 24. [PubMed:28551167]
  4. Yannuzzi NA, Freund KB: Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol. 2019 Jul 24;13:1323-1329. doi: 10.2147/OPTH.S184706. eCollection 2019. [PubMed:31413539]
  5. Ryman JT, Meibohm B: Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. doi: 10.1002/psp4.12224. Epub 2017 Jul 29. [PubMed:28653357]
  6. FDA Approved Drug Products: Brolucizumab Intravitreal Injection [Link]
  7. Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration [Link]
RxNav
2204915
Wikipedia
Brolucizumab
AHFS Codes
  • 52:92.00 — EENT Drugs, Miscellaneous
FDA label
Download (538 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatmentAge-Related Macular Degeneration (ARMD) / Eye Diseases / Macular Degeneration / Retinal Degenerations / Retinal Diseases / Wet Macular Degeneration1
4Not Yet RecruitingTreatmentWet Macular Degeneration1
4RecruitingTreatmentDystrophy, Retinal1
4RecruitingTreatmentNeovascular Age-Related Macular Degeneration2
3Active Not RecruitingTreatmentAge-Related Macular Degeneration (ARMD)1
3Active Not RecruitingTreatmentDiabetic Macular Edema (DME)2
3CompletedTreatmentAge-Related Macular Degeneration (ARMD) / Eye Diseases / Macular Degeneration / Retinal Degenerations / Retinal Diseases / Wet Macular Degeneration1
3CompletedTreatmentNeovascular Age Related Macular Degeneration / Neovascular Age-Related Macular Degeneration1
3CompletedTreatmentNeovascular Age-Related Macular Degeneration1
3CompletedTreatmentNeovascular Age-Related Macular Degeneration / Subfoveal Choroidal Neovascularization2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntravitreal
Injection, solutionIntravitreal120 MG/ML
Injection, solutionIntravitreal6 mg/0.05mL
SolutionIntravitreal6 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Details1. Vascular endothelial growth factor A
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Vascular endothelial growth factor receptor binding
Specific Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of...
Gene Name
VEGFA
Uniprot ID
P15692
Uniprot Name
Vascular endothelial growth factor A
Molecular Weight
27042.205 Da
References
  1. FDA Approved Drug Products: Brolucizumab Intravitreal Injection [Link]

Drug created on May 20, 2019 08:31 / Updated on January 25, 2021 22:38